NICE

What are biosimilars and generics? And how could they save the NHS up to £1 billion over five years? Our explainer breaks it down: indepth.nice.org.uk/biosimilars-an…

NICE has implemented new measures to evaluate medicine cost-effectiveness, following a policy change increasing evaluation thresholds to £25,000–£35,000 per quality-adjusted life year gained — improving patient access to treatments. Learn more: nice.org.uk/news/articles/…

Healthtech developers with a NICE early use recommendation – new dedicated NIHR funding is now available to help generate the evidence needed for wider NHS adoption⤵️

Healthtech developers with a NICE early use recommendation – new dedicated NIHR funding is now available to help generate the evidence needed for wider NHS adoption⤵️

Also launching today is an improved MHRA-NICE Integrated Scientific Advice service, designed to help companies meet Aligned Pathway timelines by clarifying regulatory and HTA evidence requirements early. Fees are 25% lower than before — and 40% lower for SMEs.

From today, the @MHRAgovuk-NICE Aligned Pathway is open, delivering parallel decisions on licencing and value to get medicines to NHS patients 3-6 months sooner. No separate application or fee needed for eligible topics. Learn more: nice.org.uk/news/blogs/mhr…

View NICE's strategic priorities for guidance development in 2026-27 here: nice.org.uk/what-nice-does…

View NICE's priority topics for 2026-27 here: nice.org.uk/what-nice-does…

We’ve updated our forward view, which sets out the areas we will prioritise each year. A new section highlights the strategic areas we’ll be focusing on in guidance development, such as: ✅the 10 Year Health Plan ✅the modern service frameworks ✅and biosimilars and generics

We've recommended semaglutide (Wegovy) on the NHS to protect heart patients from a second heart attack or stroke. Here's what you need to know: nice.org.uk/news/articles/…

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause. Lear more in final guidance published today: nice.org.uk/guidance/ta114…

For the first time, endometriosis now has its own fertility pathway in NICE guidance: nice.org.uk/news/articles/… #EndometriosisActionMonth #EndometriosisDoesntWait

Things are changing at NICE. Following the 10 Year Health Plan, we're strengthening our role in getting the best healthtech to patients. 🎧Hear from people whose lives have been transformed by NICE-recommended healthtech in the latest #NICETalks: soundcloud.com/nicecomms/heal…

Almost 30,000 people with the breathing condition COPD are set to benefit after we recommended a new targeted treatment that can be taken at home. Learn more about dupilumab: nice.org.uk/guidance/ta114…

Better data means more accurate assessments, helping ensure NHS resources go to treatments that make the biggest difference to people's lives. We welcome the new EQ-5D-5L value set for the UK as announced by @EuroQol. Sophie Cooper explains more: nice.org.uk/news/blogs/bet…

We're at #REWIRED26 in Birmingham. Developing or adopting digital tech? Find us at stand F01 discuss how we can help. 👉Explore support: nice.org.uk/what-nice-does…

Thousands of people with head and neck cancer are set to benefit after we recommended a new treatment that can be taken before and after surgery. Find out more about pembrolizumab: nice.org.uk/guidance/indev…

"Fear of a second stroke doesn't dictate my life anymore." After his stroke, Peter lived with uncertainty. An implantable cardiac monitor detected atrial fibrillation after a year of monitoring. He got the right treatment and his life back. Peter's story indepth.nice.org.uk/PetersStory/in…

The Health Economics Methods Advisory group (HEMA) is an international collaboration to research and evaluate health technology assessment methods. Join a webinar to discuss the findings of its first report on Monday 23 March @CDA_AMC @icer_review us02web.zoom.us/webinar/regist…

Earlier this week we published final guidance recommending ruxolitinib for treating non-segmental vitiligo in people 12 years and over⬇️ nice.org.uk/guidance/ta1140

Today’s new guidance has been welcomed by patients and charities, including the Rose Woodward, CEO of @ACTION4KC, who was a member of our guideline committee.

We have also published our first quality standard covering kidney cancer. It sets out a series of statements describing high-quality care in priority areas for improvement. Read more: nice.org.uk/guidance/qs215…

First kidney cancer guideline published by NICE: nice.org.uk/guidance/ng256… It recommends offering biopsies to more people with suspected renal cell carcinoma, which could see biopsies rise from around 600 to 1,200 a year, reducing unnecessary surgeries for benign lesions.